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Abstract The prevalence of Clostridium difficile infection
(CDI) in pediatric patients with inflammatory bowel
disease (IBD) is still not sufficiently recognized. We
assessed the prevalence of CDI and recurrences in
outpatients with IBD. In addition, the influence of IBD
therapy on CDI and antimicrobial susceptibility of the
potentially causative C. difficile strains was assessed. This
was a prospective, single-center, observational study. All
specimens were obtained between January 2005 and
January 2007 from the IBD outpatient service and
screened for C. difficile and its toxins. C. difficile isolates
were genotyped by PCR ribotyping. Diagnosis of Crohn’s
disease (CD) and ulcerative colitis (UC) was based on
Porto criteria. Severity of disease was assessed using the
Hyams scale (for Crohn’s disease) and the Truelove–Witts
scale (for ulcerative colitis). One hundred and forty-three
fecal samples from 58 pediatric IBD patients (21 with
Crohn’s disease and 37 with ulcerative colitis) were
screened. The risk of C. difficile infection was 60% and
was independent of disease type (CD or UC) (χ2=2.5821,
df=3, p=0.4606). About 17% of pediatric IBD patients
experienced a recurrence of CDI. All C. difficile strains were
susceptible to metronidazole, vancomycin and rifampin. A
high prevalence of C. difficile infection and recurrences in
pediatric outpatients with IBD was observed, independent of
disease type. There was no significant correlation between C.
difficile infection and IBD therapy. PCR ribotyping revealed
C. difficile re-infection and relapses during episodes of IBD
in pediatric outpatients.
Introduction
Clostridium difficile (C. difficile) strains cause severe
diarrhea and colitis in both adults and children [1, 2].
Clinically important C. difficile strains usually produce two
toxins: toxin A (TcdA)—an enterotoxin—and toxin B
(TcdB)—a cytotoxin. These toxins are the main virulence
factors of C. difficile, responsible for symptoms of diarrhea
and inflammation [3, 4]. The epidemiology of C. difficile
infection (CDI) has changed during the past decade.
Traditional risk factors for C. difficile-associated disease
are use of broad-spectrum antibiotic, chemotherapy, age
over 65 years, and long-term hospitalization [5]. It was
recently demonstrated that the use of immunomodulators
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and the presence of inflammatory bowel diseases (IBD) are
important risk factors for the development of CDI [5–7].
The two major types of IBD are ulcerative colitis (UC)
and Crohn’s disease (CD). Patients with IBD are often
hospitalized with worsening diarrhea, which is attributable
to progression of their underlying disease. Whether
infection plays a role in this process is ill-defined. Potential
risk factors for the acquisition of C. difficile infection in
IBD patients include drugs used in medical treatment (e.g.,
sulfasalazine), which might alter the intestinal flora and
promote colonization, altered immune status possibly
related to therapeutic agents, nutritional status and
frequent hospitalizations [8]. IBD patients with colonic
involvement exhibited a significant association with
development of C. difficile infection, with both Crohn’s
disease and ulcerative colitis [6].
Clostridium difficile infection may be difficult to
distinguish from an IBD onset or relapse, given the similar
symptoms of diarrhea, abdominal pain, and low-grade
fever. In addition, CDI might be more commonly
community-acquired than hospital-acquired [6, 7, 9]. The
frequency of C. difficile infection in IBD pediatric patients
has not been established precisely, but seemed to be higher
than in adults [10].
The aim of the study was to determine the prevalence of
C. difficile infection in pediatric outpatients with active and
inactive (in remission) IBD. Also, this study determined
whether diarrhea episodes were due to C. difficile re-
infection or relapse. In addition, the influence of treatment
on C. difficile infection and the antimicrobial susceptibility
of C. difficile strains were assessed.
Materials and methods
Patients and specimens
This was a prospective, single-center, observational study.
All specimens were submitted and processed immediately
from the out-patients service of the Department of
Pediatric Gastroenterology and Nutrition in Warsaw,
Poland between January 2005 and January 2007. We
collected data on patient age and gender, antibiotic
treatment and hospitalization within the 3 months before
the time of C. difficile diagnosis. All drugs used by
patients were recorded. Diagnosis of Crohn’s disease and
ulcerative colitis was based on clinical signs and symp-
toms combined with endoscopic, histological, and radio-
logical results, which were interpreted according to the
Porto criteria [11]. We used the modified Truelove and
Witts activity index for ulcerative colitis and pediatrically
modified Hyams activity index (PCDAI) for Crohn’s
disease. Active disease was defined as symptomatic UC
with a Truelove–Witts score greater than 4 points and
symptomatic CD with a PCDAI score greater than 10 points.
The Truelove–Witts activity score is partly based on the
patient’s symptoms (number of stools, presence of blood in
the stool, fever), but also on laboratory data (hemoglobin
level, ESR) and nutritional assessment. The Hyams activity
score assesses patient’s symptoms (abdominal pain, bowel
habits, overall well-being), laboratory findings (ESR, hemo-
globin level, albumin level), physical examination of abdo-
men, presence of perianal complications, extraintestinal
manifestation, and nutritional assessment.
Clostridium difficile infection recurrences were defined
on the basis of defecation frequency as perceived by the
patient. Increases should at least last for two consecutive
days and stools should become progressively looser or new
signs of severe colitis should develop. Microbiological
evidence of the presence of toxins of C. difficile and/or the
actual presence of toxin-producing C. difficile strains after
an initial CDI treatment response should be presented. The
fecal samples from patients with an active or an inactive
form of IBD were collected in sterile universal collectors
and send to the diagnostic laboratory. Stools samples were
investigated for enteropathogenic organisms such as
toxigenic Escherichia coli, Salmonella spp., Shigella
spp., rota- and adenoviruses (VIKIA ROTA ADENO
KIT; bioMérieux, Marcy l’Etoile, France). Patients with
IBD were treated with sulfasalazine or mesalazine,
azathioprine, cyclosporine, steroids and infliximab accord-
ing to accepted clinical protocols. Patients with C. difficile
infection (TcdA/TcdB toxins and/or toxigenic strains
detection) were treated with metronidazole for 10–14 days
per one episode, which was the standard antimicrobial
treatment protocol.
Diagnosis of C. difficile infection
Diagnosis of CDI was based on a positive stool enzyme
immunoassay (EIA) and/or on the isolation of toxigenic C.
difficile strains. Either or both of the C. difficile toxins
TcdA/TcdB were detected in the fecal samples with an
enzyme immunoassay (C. difficile TOX A/B II™; TechLab,
Blacksburg, VA, USA). All fecal samples were inoculated
after enrichment (by using an alcohol-shock procedure)
onto selective Columbia Agar supplemented with
cycloserine-cefoxitin and amphotericin B (CCCA medium;
bioMérieux, Marcy l’Etoile, France) for detection of C.
difficile. Plates were incubated in an anaerobic chamber
(Forma Scientific, Marietta, GA, USA) at 37°C for 2 days
[12]. The isolates were identified as C. difficile by the
characteristic morphology of colonies, the specific horse
odor, the yellow–green fluorescence under UV light
(365 nm), Gram staining results, and biochemical tests (API
20A; bioMérieux, Marcy l’Etoile, France). For the detection
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of tcdA/tcdB and binary toxin genes (cdtA and cdtB) genes,
PCR was performed as described previously [12].
PCR ribotyping
Clostridium difficile isolates were typed by the PCR
ribotyping methods described earlier [12]. Banding patterns
were compared with those of the library of PCR ribotypes
at the ARL, Cardiff [13].
Determination of antibiotic susceptibility
Minimal inhibitory concentration (MICs) for metronidazole
(MZ), vancomycin (VA), ciprofloxacin (CI), gatifloxacin
(GA), moxifloxacin (MX), and rifampin (RI) were determined
by E-test (AB Biodisc, Solna, Sweden) according to the
manufacturer’s instructions, as described previously [12].
According to the Clinical and Laboratory Standard Institute
(CLSI) recommendations (formerly NCCLS), antibiotic
resistance was defined as follows: MIC≥32 mg/L for
metronidazole, MIC≥32 mg/L for vancomycin, MIC≥
4 mg/L for ciprofloxacin, MIC≥4 mg/L for gatifloxacin
and MIC≥4 mg/L for moxifloxacin [14]. Rifampin resis-
tance was defined as MIC≥32 mg/L in accordance with
O’Connor et al. [15].
Statistical analyses
The Chi-squared test for independence was used to verify
the hypothesis that infection C. difficile was independent
of the type of illness. The gender proportions in groups
were investigated by the Chi-squared test; for multiple
comparisons LSD post hoc Fisher’s test was used. The
constancy of variance across the four patient groups was
checked using Bartlett’s test. We used Classical Multidi-
mensional Scaling based on Hamming distance to identify
common treatment schemes. We examined infection risk
and explanatory variables using logistic regression. Yates’
correction for continuity was used when needed.
Ethical considerations
The research presented in this manuscript was approved by
the Ethics Committee on Clinical Investigation of the
Medical University of Warsaw.
Results
One hundred forty-three fecal samples collected from 58
IBD pediatric patients were screened for C. difficile toxin
TcdA/TcdB, and toxigenic C. difficile bacteria. Twenty-five
females and 33 males, aged between 3 and 18 years (mean
age 11.9 years), participated in this study. Of all patients in
the IBD group 21 had Crohn’s disease (CD) and 37 had
ulcerative colitis (UC). Baseline characteristics of pediatric
patients and stool samples are shown in Table 1. All stool
samples were negative for enteropathogenic organisms such
as toxigenic Escherichia coli, Salmonella spp., Shigella spp.,
enterotoxigenic C. perfringens, and rota- and adenoviruses
(data not shown). None of the patients required hospitaliza-
tion for more than 3 months before fecal sample collection.
Table 1 Therapeutic treatment, demographic and number of patients and faecal samples from paediatric outpatients in active (A) and inactive (I) IBD
Demographic
of patients and
therapeutic
treatment
CDa (n=21) UCa (n=37) Number of faecal
samples from female
and male and
therapeutic treatment
Faecal samples
(n=143) from
IBD patients
CDa (n=49) UCa (n=94)
Ab
(n=11)
Ib
(n=10)
Ab
(n=16)
Ib
(n=21)
Ac
(n=62)
I c
(n=81)
Ac
(n=18)
Ic
(n=31)
Ac
(n=44)
Ic
(n=50)
Male (n=33) 6 8 10 9 Male (n=82) 36 46 11 25 25 21
Female (n=25) 5 2 6 12 Female (n=61) 26 35 7 6 19 29
Age 3-18 yr Age 3-18 yr
Sulfasalazine 3 0 4 16 Sulfasalazine 23 43 3 3 20 40
Mesalazine 6 7 13 6 Mesalazine 33 36 12 26 21 10
Azathioprine 8 7 10 10 Azathioprine 38 53 14 30 24 23
Cyclosporine 0 0 2 1 Cyclosporine 3 1 0 0 3 1
Steroids 6 3 13 6 Steroids 41 22 7 5 34 17
Infliximab 1 1 0 0 Infliximab 1 1 1 1 0 0
Abbreviations: a CD or UC - patients with Crohn’s disease or ulcerative colitis, respectively
b number of patients (female or male) in active (A) or inactive (I) IBD.
c number of fecal samples in active (A) or inactive (I) IBD.
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Clostridium difficile toxins were identified in 60% of the
stool samples (86 out of 143) and in 69% of the pediatric
patients (40 out of 58) participating in this study. The risk
of C. difficile infection was independent of disease type
(Crohn’s disease or ulcerative colitis; χ2=2.5821, df=3, p=
0.4606). TcdA/TcdB detection rates and C. difficile culture
data are shown in Table 2. A highly significant relationship
between the presence of C. difficile toxins and IBD, both
active (p<0.0001) and inactive (p<0.0001), was observed.
In addition, no significant correlation was found between C.
difficile infection and IBD therapy, which included
sulfasalazine (p= 0.1856), mesalazine (p= 0.129),
azathioprine (p=0.341), and steroids (p=0.8255).
Cyclosporine and infliximab were excluded from the
statistical analysis because of their insignificant numbers.
From EIA-positive stool samples we cultured 18 C.
difficile strains. PCR-ribotyping identified five different
ribotypes: three among the toxigenic (014, 018, 046) and
two among the non-toxigenic strains (010, 035). The most
predominant ribotype was 014 (A+B+CDT−) accounting
for 50% of all strains. Two to seven clinical recurrences of
C. difficile infection were observed during the study
period among IBD patients and 17% of all 58 patients
had recurrences (Table 2). Strains isolated during the first
episode of C. difficile infection usually belonged to PCR-
ribotype 014, and strains from the re-infections belonged
to different ribotypes (ribotype 018 or 046). Colonization
of the gastrointestinal tract with non-toxigenic C. difficile
strains (ribotype 010 or 035) was very frequent among the
IBD patients.
All C. difficile strains were susceptible to metronidazole
(MIC range 0.023–0.38 mg/L), vancomycin (MIC range
0.25–1.5 mg/L), rifampin (MIC=0.002 mg/L for all
strains), moxifloxacin (MIC range 0.064–1.5 mg/L) and
gatifloxacin (MIC range 0.5–1.5 mg/L), but were resistant
to ciprofloxacin (MIC≥32 mg/L).
Discussion
In our study, the prevalence of C. difficile infection in
pediatric outpatients with IBD was assessed as being 69%.
This is clearly higher than reported in the only previously
published pediatric study (27.8%) [10] or among adults
with IBD (4.2–5.8%) [6, 7]. Several factors could explain
our results. First, the majority of our children were
outpatients and previous studies showed that the majority
of IBD patients contract C. difficile infections outside the
hospital [6, 7]. A second possible reason is the way we
controlled our patients: a fecal sample for toxin detection
was collected during every follow-up visit, which are
regularly arranged even in the absence of aggravation.
Finally, the incidence of C. difficile infection in Polish
pediatric IBD patients is unknown, but it could simply be
higher than in Western Europe or the United States.
Large population-based studies have demonstrated that
CDI is more common in ulcerative colitis (UC) than Crohn’s
disease (CD) [6, 7]. Our data showed that no specific type of
IBD in our pediatric outpatients predisposed to C. difficile
infection; the risk of C. difficile infection was the same in
both UC and CD. This can be explained by the fact that the
majority of our CD patients had colonic disease. IBD
patients with colonic involvement exhibited a significant
association with the development of C. difficile infection
[16]. However, the lack of a comparator population (patients
without IBD) limits the strength of the study.
Table 2 Summary of detection of TcdA/TcdB toxins and/or toxigenic C. difficile strains in specimens of pediatric outpatients with IBD and
recurrences of CDI
Number of
faecal
samplesa
Number (%) of positive
faecal samples for CDIc
Number
of
patientsd
Number (%) of
positive patients for
CDIc
Number of patients
with recurrencese
Distribution of common genotypes
in patients with recurrences of CDIf
IBDb n=143 86/143 (60%) IBDbn=58 40/58 (69%) 10/58 (17%) 014
n=62 (A) 42/86 (49%) n=27 (A) 18 (66%) 5/27 (18%) 014
n=81 (I) 44/86 (51%) n=31 (I) 22 (71%) 5/31 (16%) 014/010
CDb n=49 29/49 (59%) CDb n=21 13 (62%) 3/21 (14%) 014
n=18 (A) 12/29 (41%) n=11 (A) 7 (64%) 1/11 (9%) 014
n=31 (I) 17/29 (59%) n=10 (I) 6 (60%) 2/10 (20%) 014/010
UCb n=94 57/94 (61%) UCb n=37 27 (73%) 7/37 (20%) 014
n=44 (A) 30/57 (53%) n=16 (A) 12 (75%) 4/16 (25%) 014
n=50 (I) 27/57 (47%) n=21 (I) 15 (71%) 3/21 (14%) 014
Abbreviations: a number of fecal samples received from patients with IBD active (A) or inactive (I), b IBD -inflammatory bowel disease, CD-Crohn disease,
UC-ulcerative colitis, cC. difficile toxins and/or toxigenic C. difficile strains, d -number of patients with IBD (CD or UC) active (A) or inactive (I), f PCR-
ribotype of C. difficile strains; e number of patients with recurrences with IBD (A) or (I); f PCR-ribotypes caused recurrences in patients with IBD (A) or (I)
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We detected no significant correlation between the risk
of C. difficile infection and IBD therapy, including anti-
inflammatory drugs (sulfasalazine, mesalazine) or
immune-modulating drugs (azathioprine, systemic
steroids). These findings confirmed results from the
published pediatric study [10], but not those from adult
studies, which had shown that immune modulators were
risk factors for C. difficile infection in hospitalized IBD
patients [6, 17]. The impact of ongoing immune modula-
tion on C. difficile infection in adult outpatients is as yet
undefined.
Two, 3, 4, and 7 recurrences of C. difficile infection were
observed during the study period in 1, 4, 4, and 1 patients
respectively. Recurrences of C. difficile infection among
IBD patients are a serious problem, especially for patients
with 3 or more episodes [18]. Issa et al. demonstrated that
59% of the patients with IBD had a clinical recurrence
within 1 month of the initial resolution of symptoms using
metronidazole or vancomycin [19]. Another 22% had
persistent symptoms with frequent relapses. The data
regarding the recurrence rate of C. difficile in the adult
IBD population are limited and there are no data at all for
pediatric IBD patients [16]. Recurrences of C. difficile may
be explained either by the endogenous persistence of a C.
difficile strain (relapse) or by acquisition of a new strain
from the environment (re-infection) [20]. We have shown
both scenarios to be relevant. However, our data are limited
because of small numbers of C. difficile isolates.
Two reports have previously shown that 38–56% of
recurrent C. difficile infection were in fact due to re-
infections [21, 22]. Barbut et al. showed that 48.4% of
clinical recurrences among patients hospitalized in different
clinical units in France were in fact re-infections with a
different strain of C. difficile [20]. Our results point to
frequent (re-)infection caused by one type of C. difficile
(PCR-ribotype 014). Relapses followed each other more
closely (less than 1 month between episodes) than re-
infections. Metronidazole and oral vancomycin have been
shown to be effective in the treatment of C. difficile-
associated diseases, but symptomatic recurrences occur in
15–30% of cases [21–23].
Currently, there are no specific antibiotic regimens
recommended for IBD patients suffering from CDI.
Metronidazole is still considered the first-line therapy for
C. difficile infection, so all of our patients were treated with
metronidazole. In spite of reports that metronidazole
treatment for C. difficile infection is effective in only 50%
of patients [6], we did not observe resistance to metroni-
dazole and vancomycin in pediatric C. difficile strains [24].
We observed that all strains isolated from pediatric IBD
outpatients were susceptible to rifampin.
Fluoroquinolones are a mainstay of treatment in patients
with IBD, particularly for management of suppurative
complications such as abscesses in Crohn’s disease [6].
Our findings confirmed that the resistance of C. difficile to
ciprofloxacin was very frequent [9, 24, 25]. However,
resistance to newer fluoroquinolones such as gatifloxacin
and moxifloxacin was not observed among strains isolated
from our patients with IBD.
Conclusions
We report a high prevalence of CDI in pediatric outpatients
with inflammatory bowel disease, a clear risk of CDI in
both ulcerative colitis and Crohn’s disease. In addition,
there was no significant correlation between C. difficile
infection and IBD therapy, and PCR ribotyping revealed
both C. difficile re-infection and relapses during episodes of
IBD in pediatric outpatients.
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